Program
asedebart
Also written as “Lu AG13909” and “Asedebart”.
Its studies are mostly in Adrenal Hyperplasia, Congenital · Pituitary ACTH Hypersecretion, led by H. Lundbeck.
Furthest: phase 2, since Dec 20, 20223 company-led studies, 3 open or runningNext primary completion: Aug 10, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 33 open or running | phase 2since Dec 20, 2022 | Dec 20, 2022 | Aug 10, 2027phase 2 · NCT06471829 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2022First study: phase 2 study in Adrenal Hyperplasia, CongenitalFirst studyNCT05669950 · 42 planned · United States, Denmark, France and more
- Jun 18, 2024Phase 2 study in Pituitary ACTH HypersecretionNCT06471829 · 16 enrolled · United States, France, Georgia and more
- Sep 29, 2026Phase 2 study in Adrenal Hyperplasia, CongenitalNCT07859293 · 45 planned
- Oct 16, 2026Primary completion moved from 2026-09-15 to 2027-08-10Date moved laterphase 2 · +11 months · NCT06471829
Ahead
- Aug 10, 2027Primary completion: phase 2 study in Pituitary ACTH HypersecretionNCT06471829
- Jul 31, 2031Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNCT07859293
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07859293Adrenal Hyperplasia, Congenital | 2 | Not yet recruiting | Jul 31, 2031 | 45 |
| NCT06471829Pituitary ACTH Hypersecretion · United States, France, Georgia and more | 2 | Active, not recruiting | Aug 10, 2027 | 16 |
| NCT05669950Adrenal Hyperplasia, Congenital · United States, Denmark, France and more | 2 | Recruiting | Sep 30, 2026 | 42 |
How it is read
Names in the registry
- “Lu AG13909”, 2 entries
- “Asedebart”, 1 entry
Conditions, from the studies’ own filings
- Adrenal Hyperplasia, Congenital, 2 studies
- Pituitary ACTH Hypersecretion, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.